Immunogenicity of rituximab in patients with severe pemphigus

Clinical Immunology

Volumn 132, Issue 3, 2009, Pages 334-341

  Schmidt, Enno ^a   Hennig, Kirsten ^b   Mengede, Christian ^c   Zillikens, Detlef ^a   Kromminga, Arno ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b IPM   (Germany)

^c Squarix Biotechnology   (Germany)

Author keywords

Autoantibody; Immunogenicity; MabThera ; Pemphigus; Rituxan ; Treatment

Indexed keywords

AUTOANTIBODY; DESMOGLEIN 1; DESMOGLEIN 3; IMMUNOGLOBULIN F(AB) FRAGMENT; RITUXIMAB;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; MALE; PEMPHIGUS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; DESMOGLEIN 1; DESMOGLEIN 3; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PEMPHIGUS; RECURRENCE;

EID: 67651154129     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.05.007     Document Type: Article

References (39)

1. Stanley J.R., and Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N. Engl. J. Med. 355 (2006) 1800-1810
2. Grando S.A. Cholinergic control of epidermal cohesion. Exp. Dermatol. 15 (2006) 265-282
3. Martin L.K., Werth V., Villanueva E., Segall J., and Murrell D.F. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst. Rev. 1 (2009) CD006263
4. Bystryn J.C., and Rudolph J.L. Pemphigus. Lancet 366 (2005) 61-73
5. Harman K.E., Albert S., and Black M.M. Guidelines for the management of pemphigus vulgaris. Br. J. Dermatol. 149 (2003) 926-937
6. Schmidt E., Brocker E.B., and Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin. Rev. Allergy Immunol. 34 (2008) 56-64
7. Schmidt E., and Goebeler M. CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev. Dermatol. 3 (2008) 259-278
8. Gurcan H.M., Keskin D.B., Stern J.N., Nitzberg M.A., Shekhani H., and Ahmed A.R. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 9 (2009) 10-25
9. Anhalt G.J., Labib R.S., Voorhees J.J., Beals T.F., and Diaz L.A. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N. Engl. J. Med. 306 (1982) 1189-1196
10. Ahmed A.R., Spigelman Z., Cavacini L.A., and Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355 (2006) 1772-1779
11. Joly P., Mouquet H., Roujeau J.C., D'Incan M., Gilbert D., Jacquot S., Gougeon M.L., Bedane C., Muller R., Dreno B., Doutre M.S., Delaporte E., Pauwels C., Franck N., Caux F., Picard C., Tancrede-Bohin E., Bernard P., Tron F., Hertl M., and Musette P. A single cycle of rituximab for the treatment of severe pemphigus. N. Engl. J. Med. 357 (2007) 545-552
12. Schmidt E., Seitz C.S., Benoit S., Brocker E.B., and Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br. J. Dermatol. 156 (2007) 352-356
13. Shimanovich I., Nitschke M., Rose C., Grabbe J., and Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br. J. Dermatol. 158 (2008) 382-388
14. Aboobaker J., Wojnarowska F.T., Bhogal B., and Black M.M. Chronic bullous dermatosis of childhood-clinical and immunological features seen in African patients. Clin. Exp. Dermatol. 16 (1991) 160-164
15. Vugmeyster Y., and Howell K. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int. Immunopharmacol. 4 (2004) 1117-1124
16. Leandro M.J., Cambridge G., Ehrenstein M.R., and Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54 (2006) 613-620
17. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., and Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 3580-3590
18. Mouquet H., Musette P., Gougeon M.L., Jacquot S., Lemercier B., Lim A., Gilbert D., Dutot I., Roujeau J.C., D'Incan M., Bedane C., Tron F., and Joly P. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J. Invest. Dermatol. 128 (2008) 2859-2869
19. Browning J.L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev., Drug Discov. 5 (2006) 564-576
20. Manshouri T., Do K.A., Wang X., Giles F.J., O'Brien S.M., Saffer H., Thomas D., Jilani I., Kantarjian H.M., Keating M.J., and Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101 (2003) 2507-2513
21. Albert D., Dunham J., Khan S., Stansberry J., Kolasinski S., Tsai D., Pullman-Mooar S., Barnack F., Striebich C., Looney R.J., Luning Prak E.T., Kimberly R., Zhang Y., and Eisenberg R. Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann. Rheum. Dis. 67 (2008) 1724-1731
22. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., and Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2572-2581
23. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., Sloand J.A., Rosenblatt J., and Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50 (2004) 2580-2589
24. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., Wey K., Royston I., Davis T., and Levy R. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
25. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., Vissink A., Kallenberg C.G., and Bootsma H. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 52 (2005) 2740-2750
26. Smith K.G., Jones R.B., Burns S.M., and Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54 (2006) 2970-2982
27. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., Shima Y., Takada K., Matsumoto I., Saito K., and Koike T. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17 (2007) 191-197
28. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D., and Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 (1998) 2825-2833
29. Blasco H., Lalmanach G., Godat E., Maurel M.C., Canepa S., Belghazi M., Paintaud G., Degenne D., Chatelut E., Cartron G., and Le Guellec C. Evaluation of a peptide ELISA for the detection of rituximab in serum. J. Immunol. Methods 325 (2007) 127-139
30. Bourdage J.S., Cook C.A., Farrington D.L., Chain J.S., and Konrad R.J. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods 327 (2007) 10-17
31. Piro L.D., White C.A., Grillo-Lopez A.J., Janakiraman N., Saven A., Beck T.M., Varns C., Shuey S., Czuczman M., Lynch J.W., Kolitz J.E., and Jain V. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10 (1999) 655-661
32. Teeling J.L., Mackus W.J., Wiegman L.J., van den Brakel J.H., Beers S.A., French R.R., van Meerten T., Ebeling S., Vink T., Slootstra J.W., Parren P.W., Glennie M.J., and van de Winkel J.G. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177 (2006) 362-371
33. Beum P.V., Kennedy A.D., and Taylor R.P. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Methods 289 (2004) 97-109
34. Hong K., Presta L.G., Lu Y., Penn A., Adams C., Chuntharapai A., Yang J., Wong W.L., and Meng Y.G. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J. Immunol. Methods 294 (2004) 189-197
35. Cragg M.S., Bayne M.B., Tutt A.L., French R.R., Beers S., Glennie M.J., and Illidge T.M. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104 (2004) 2540-2542
36. Cartron G., Blasco H., Paintaud G., Watier H., and Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use?. Crit. Rev. Oncol. Hematol. 62 (2007) 43-52
37. Saito K., Nawata M., Iwata S., Tokunaga M., and Tanaka Y. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology (Oxford) 44 (2005) 1462-1464
38. Baert F., Noman M., Vermeire S., Van Assche G., Carbonez D.H.G.A., and Rutgeerts P., Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348 (2003) 601-608
39. Chung C.H., Mirakhur B., Chan E., Le Q.T., Berlin J., Morse M., Murphy B.A., Satinover S.M., Hosen J., Mauro D., Slebos R.J., Zhou Q., Gold D., Hatley T., Hicklin D.J., and Platts-Mills T.A. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 358 (2008) 1109-1117